WO2012064303A2 - Improved montelukast combinations - Google Patents
Improved montelukast combinations Download PDFInfo
- Publication number
- WO2012064303A2 WO2012064303A2 PCT/TR2011/000245 TR2011000245W WO2012064303A2 WO 2012064303 A2 WO2012064303 A2 WO 2012064303A2 TR 2011000245 W TR2011000245 W TR 2011000245W WO 2012064303 A2 WO2012064303 A2 WO 2012064303A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- sodium
- agents
- montelukast
- lubricant
- Prior art date
Links
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title claims abstract description 36
- 229960005127 montelukast Drugs 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 119
- 238000009472 formulation Methods 0.000 claims abstract description 111
- 239000013543 active substance Substances 0.000 claims abstract description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 17
- 239000000314 lubricant Substances 0.000 claims description 41
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims description 34
- 229960001271 desloratadine Drugs 0.000 claims description 34
- 239000000454 talc Substances 0.000 claims description 18
- 229910052623 talc Inorganic materials 0.000 claims description 18
- 229940033134 talc Drugs 0.000 claims description 18
- -1 glidants Substances 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- 239000007884 disintegrant Substances 0.000 claims description 12
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 10
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229920002545 silicone oil Polymers 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 210000002345 respiratory system Anatomy 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 230000003711 photoprotective effect Effects 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 206010049153 Allergic sinusitis Diseases 0.000 claims description 2
- 208000009657 Aspirin-Induced Asthma Diseases 0.000 claims description 2
- 206010003557 Asthma exercise induced Diseases 0.000 claims description 2
- 239000004135 Bone phosphate Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 206010039094 Rhinitis perennial Diseases 0.000 claims description 2
- 208000036284 Rhinitis seasonal Diseases 0.000 claims description 2
- 239000004115 Sodium Silicate Substances 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- YHGREDQDBYVEOS-UHFFFAOYSA-N [acetyloxy-[2-(diacetyloxyamino)ethyl]amino] acetate Chemical compound CC(=O)ON(OC(C)=O)CCN(OC(C)=O)OC(C)=O YHGREDQDBYVEOS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002518 antifoaming agent Substances 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 claims description 2
- 235000001465 calcium Nutrition 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 claims description 2
- 239000001175 calcium sulphate Substances 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- ILWNTWRKKKGJCG-UHFFFAOYSA-L calcium;sulfate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]S([O-])(=O)=O ILWNTWRKKKGJCG-UHFFFAOYSA-L 0.000 claims description 2
- 229940099112 cornstarch Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- 229940096516 dextrates Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 229960002598 fumaric acid Drugs 0.000 claims description 2
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 claims description 2
- 229920006158 high molecular weight polymer Polymers 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 235000001055 magnesium Nutrition 0.000 claims description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 2
- 239000011654 magnesium acetate Substances 0.000 claims description 2
- 235000011285 magnesium acetate Nutrition 0.000 claims description 2
- 229940069446 magnesium acetate Drugs 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
- 235000019792 magnesium silicate Nutrition 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 2
- 239000004223 monosodium glutamate Substances 0.000 claims description 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 2
- 208000022719 perennial allergic rhinitis Diseases 0.000 claims description 2
- 229960005455 polacrilin Drugs 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 229920001592 potato starch Polymers 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229910001388 sodium aluminate Inorganic materials 0.000 claims description 2
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 2
- 229960005055 sodium ascorbate Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 229960001790 sodium citrate Drugs 0.000 claims description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 229940100445 wheat starch Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 244000061456 Solanum tuberosum Species 0.000 claims 1
- 235000002595 Solanum tuberosum Nutrition 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- 239000000306 component Substances 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 19
- 229960001951 montelukast sodium Drugs 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000012535 impurity Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 150000003462 sulfoxides Chemical group 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000007916 tablet composition Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 description 3
- QGLIUOLEDZMNSF-UHFFFAOYSA-N 4-(8-chloro-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridin-11-ylidene)piperidine-1-carbaldehyde Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCN(C=O)CC1 QGLIUOLEDZMNSF-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- QYOIIAUGMZLCEO-JGCGQSQUSA-N CC(C)(c1c(CC[C@H](c2cccc(CCc(cc3)nc4c3ccc(Cl)c4)c2)SCC2(CC(O)=O)CC2)cccc1)O Chemical compound CC(C)(c1c(CC[C@H](c2cccc(CCc(cc3)nc4c3ccc(Cl)c4)c2)SCC2(CC(O)=O)CC2)cccc1)O QYOIIAUGMZLCEO-JGCGQSQUSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 description 1
- 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229960003686 chlorphenoxamine Drugs 0.000 description 1
- KKHPNPMTPORSQE-UHFFFAOYSA-N chlorphenoxamine Chemical compound C=1C=C(Cl)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KKHPNPMTPORSQE-UHFFFAOYSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- ZDIGNSYAACHWNL-HNNXBMFYSA-N dexbrompheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 ZDIGNSYAACHWNL-HNNXBMFYSA-N 0.000 description 1
- 229960002691 dexbrompheniramine Drugs 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/2036—Silicones; Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Definitions
- Montelukast formulations of the present invention comprise at least one other pharmaceutically acceptable excipient in addition to the lubricant.
Abstract
The present invention relates to stabile montelukast formulations with improved flow characteristics which are produced without causing incompatibility with excipients; and combinations of these formulations with at least one other active agent.
Description
IMPROVED MONTELUKAST COMBINATIONS
The present invention relates to pharmaceutical formulations designed to remove negative effects of excipients, which are used in the formulations comprising montelukast and/or a pharmaceutically acceptable salt thereof and at least one other active agent, on the active agent.
Montelukast (Formula I) is a leukotriene receptor antagonist which was firstly disclosed in the patent numbered EP480717 Al:
Formula (I) Montelukast is an orally used, strong and selective antagonist of leukotriene D4 (LTD4) which is effective on cysteinyl leukotriene receptor (CysLT]) in the respiratory tract. Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are strong inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT) receptors located in the respiratory tract and lead to a series of respiratory tract activities such as bronchoconstriction, intensive mucus secretion, vascular permeability and accumulation of eosinophils.
However, the active agent montelukast is highly incompatible with excipients used in pharmaceutical formulations. This incompatibility induces fast disintegrations in the end product. The most important impurity generated with the disintegration of montelukast sodium is sulfoxide impurity illustrated in the following formula (II):
Formula (II)
This sulfoxide impurity appears when the sulphide group in montelukast sodium is oxidized to sulfoxide group and it is not in an active form. However, its presence reduces the effective dose of montelukast sodium in the treatment and therefore it reduces the efficiency of the treatment.
In the prior art, stabile formulations comprising excipients which are used in montelukast formulations and do not cause stability or incompatibility problems with the active agent have been designed. For instance, the patent application numbered WO/2010/041277 discloses tablet formulations which comprise montelukast, microcrystalline cellulose and a flavoring agent together with magnesium stearate.
The application WO/2007/092031 discloses pharmaceutical compositions of montelukast which do not comprise microcrystalline cellulose. In this application, magnesium stearate is used as lubricant.
Montelukast sodium is currently marketed in chewable tablet, film coated tablet and pediatric granule form under the trade name Singulair®. Film coated Singulair® formulations comprise microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose as excipient; and magnesium stearate as lubricant. However, the inventors have seen that use of magnesium stearate as a lubricant in the production of montelukast sodium formulations leads to incompatibility in the pharmaceutical composition and also the rate of sulfoxide impurity is higher than expected.
Use of magnesium stearate results in faster degradation of montelukast sodium, which is considerably susceptible to and highly incompatible with pharmaceutical excipients, than expected.
In addition, use of magnesium stearate as a lubricant in formulations does not provide sufficient flow to formulations; therefore, the formulations produced adhere to metal members through the production line. This kind of adhesion problem causes loss of active ingredient and thus, reduction of bioavailability. The inventors have developed new formulations by using a pharmaceutically acceptable lubricant or lubricant combinations which would not cause incompatibility and degradation in order to provide sufficient fluidity in montelukast formulations. The said formulations are also convenient to use with at least one other active agent.
Detailed Description of the Invention The present invention relates to stabile montelukast formulations with improved flow characteristics which are produced without causing incompatibility with excipients; and combinations of these formulations with at least one other active agent.
In the formulations produced according to the invention, it has been seen that use of a lubricant selected from a group comprising silicone oil, siliconized talc or liquid paraffin or binary or ternary combinations thereof does not cause any incompatibility and/or degradation in the formulations.
HPLC measurements which were taken after the montelukast formulations of the present invention were kept under accelerated storage conditions have indicated that sulfoxide impurity is below 0.6% in the formulations. The term "accelerated storage conditions" used herein refers to storage of formulations at 60% of relative humidity and at 45 °C for 4 weeks.
In addition, use of a lubricant selected from a group comprising silicone oil, siliconized talc or liquid paraffin or binary or ternary combinations thereof prevented adhesion to the machines during the process and minimized active agent loss. The lubricants used formed a considerably smooth film layer on montelukast particles and thus provided to improve flow characteristics.
The amount of the lubricant selected from a group comprising silicone oil, siliconized talc or liquid paraffin or binary or ternary combinations thereof which is used as lubricant in the formulations of the present invention is in the range of 0.1 to 10 % by weight, preferably in the range of 0.1 to 5 % by weight, more preferably in the range of 2 to 5 % by weight.
The term "montelukast" used throughout the text refers to montelukast or its pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer or a combination thereof. Preferably, montelukast is used in sodium salt form in the formulations of the present invention. Montelukast sodium used in the formulations of the present invention is in the range of 1 to 30%, preferably in the range of 1 to 20%, more preferably in the range of 1 to 10% by weight.
The term "silicone oil" used herein refers to dimethicone and/or silicone analogs of carbon based organic compounds including simethicone which is activated form of dimethicone.
Formulations of the present invention can comprise at least one other pharmaceutically acceptable lubricant in addition to these lubricants.
Other lubricants that can be used in the formulations of the present invention can be selected from the substances such as lauric acid, palmitic acid, stearic acid, behenic acid and/or pharmaceutically acceptable salts thereof; siliconized talc, simethicone, dimethicone, liquid paraffin, sodium stearyl fumarate, sodium lauryl sulfate, magnesium lauryl sulfate, magnesium stearate, lecithine, L-leucine, phosphatidylcholines, phosphateidylglycerides, triglycerides and the said lubricant is used in the range of 0.1 to 5% by weight in the case of using a second lubricant selected from the group stated above in addition to lubricant/lubricants used in the formulations.
Montelukast formulations of the present invention comprise at least one other pharmaceutically acceptable excipient in addition to the lubricant.
Said excipients are selected from a group comprising disintegrants, viscosity enhancing agents, filling agents, drying agents, lubricants, diluents, stabilizing agents, binders, glidants, antifoaming agents, wetting agents, effervescent combinations, sweeteners and flavoring agents. The excipients preferred in montelukast formulations of the present invention are least one binder, at least one diluent, at least one disintegrant; and the formulations can optionally comprise at least one other excipient.
The formulations of the present invention are combined with a second active agent. Nasal decongestants, leukotriene receptor antagonists, antihistaminics, antidepressants can be used as the second active agent.
The second active agent used in montelukast formulations of the present invention is preferably an antihistaminic selected from a group comprising diphenhydramine, dimenhydrinate, carbinoxamine, chlorphenoxamine, mepyramine, antazoline, triple amine, dexchlorpheniramine, dexbrompheniramine, pheniramine, buclizine, hydroxyzine, cinnarizine, meclizine, alimemazine, promethazine, cyproheptadine, ebastine, astemizole, acrivastin, loratadine, desloratadine, ketotifen, cetirizine, levocetirizine or pharmaceutically acceptable salts, solvates, derivatives, polymorphs, hydrates or enantiomers thereof.
The second active agent preferred is desloratadine or a pharmaceutically acceptable derivative thereof. The second active agent in the formulations of the present invention can be used with montelukast together, in sequence or separately.
However, the two active agents are formulated together or separately and combined in a single dosage form in the preferred embodiment of the present invention.
However, the inventor has seen that N-formyl desloratadine impurity which is the major degradation product formed by desloratadine degradation is out of these limits (more than 0.5% by weight) although sulphoxide impurity is at acceptable limits in the case that the formulations comprise desloratadine and montelukast sodium as active agents.
In other words, use of a lubricant selected from a group comprising silicone oil, siliconized talc or liquid paraffin or binary or ternary combinations thereof as the lubricant is not sufficient in order to obtain a stabile composition in the case that the formulations comprise desloratadine and montelukast sodium as active agents.
As a result of the studies conducted, the inventor has found that a stabile composition can be obtained by formulating the two active agents separately and by choosing the amount and type of the lubricant used in the desloratadine formulation. One characteristic of the formulations of the present invention comprising montelukast sodium and desloratadine as active agents is that the two formulations comprising the two active agents are formulated separately and compressed as bilayer tablet by being fed to tablet compression machine separately.
Another characteristic of the formulations of the present invention comprising montelukast sodium and desloratadine as active agents is that the formulations comprise desloratadine in
the range of 0.1 to 10%, preferably in the range of 0.1 to 8%, more preferably in the range of 0.5 to 5 % in proportion to total weight of the formulation.
Another characteristic of the formulations of the present invention comprising montelukast sodium and desloratadine as active agents is use of a lubricant selected from a group comprising silicone oil, siliconized talc or liquid paraffin or binary or ternary combinations thereof in montelukast formulations; and use of a lubricant selected from a group comprising talc, sodium stearyl fumarate or colloidal silicone dioxide or binary or ternary combinations thereof in desloratadine formulations.
Another characteristic of the formulations of the present invention comprising montelukast sodium and desloratadine as active agents is that total lubricant amount used in desloratadine formulations is in the range of 0.5 to 10 %, preferably in the range of 0.6 to 4%, more preferably in the range of 0.7 to 3%.
The formulations of the present invention can optionally comprise the combinations of the lubricants selected from the groups given. While the said combinations can be binary combinations such as talc and sodium stearyl fumarate; talc and colloidal silicone dioxide; colloidal silicone dioxide and sodium stearyl fumarate, they can also be a ternary combination comprising talc, sodium stearyl fumarate and colloidal silicone dioxide.
In the case of using the ternary combination as lubricant in desloratadine formulations, the weight ratio of sodium stearyl fumarate : colloidal silicone dioxide : talc comprised in the formulations is in the range of 0.2:1 :5 to 20:1 :0.2, preferably in the range of 0.5: 1 :20 to 20:1 :0.5.
Another characteristic of the formulations of the present invention comprising montelukast sodium and desloratadine as active agents is that desloratadine formulations comprise at least one other pharmaceutically acceptable excipient. Another characteristic of the formulations of the present invention comprising montelukast sodium and desloratadine as active agents is that the excipients used in desloratadine formulations are composed of at least one stabilizing agent, at least one disintegrant and at least one diluent.
The pharmaceutically acceptable disintegrants that can be used in the formulations of the present invention can be selected from polymers having high disintegrating characteristics, for
instance cross-linked hydroxypropyl cellulose, croscarmellose sodium, polyvinylpyrrolidone, high molecular weight polymers, microcrystalline cellulose, corn starch, sodium starch glycolate, povidone, alginic acid, sodium alginate.
The pharmaceutically acceptable binders that can be used in the formulations of the present invention can be selected from potato starch, wheat starch or corn starch; microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose; hydroxypropylmethyl cellulose and polyvinylpyrrolidone.
The pharmaceutically acceptable diluents that can be used in the formulations of the present invention can be selected from the substances such as lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, calcium phosphate (dibasic and/or tribasic), calcium sulphate trihydrate, calcium sulphate dihydrate, calcium carbonate, kaoline, lactilol, cellulose powder, dextrose, dextrates, dextrin, sucrose, maltose, fructose, mannitol, directly compressible mannitol, directly compressible lactose, sorbitol and xylitol.
The pharmaceutically acceptable film coating material that can be used in the formulations of the present invention is composed of the following components and/or combinations thereof: lactose, hydroxypropyl methyl cellulose, triacetine, titanium dioxide, polyvinyl alcohol, talc, lecithin, polyethylene glycol.
The pharmaceutically acceptable stabilizing agent and/or agents that can be used in the formulations of the present invention can be selected from antioxidants, chelating agents, alkalinizing agents and photoprotectives.
The antioxidants can be selected from substances such as butylated hydroxy anisole (BHA), sodium ascorbate, butylated hydroxy toluene (BHT), sodium sulfite, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithine, ascorbyl palmitate, ethylendiamine tetraacetate. The chelating agents can be selected from disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or combinations thereof. These agents prevent oxidation by surrounding and masking the metal ions which can catalyze the oxidation process.
The alkalinizing agents can be selected from alkaline metal salts such as sodium carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium
phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophospate, calcium hydrogen phosphate dehydrate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; and organic compounds such as primary, secondary and tertiary amines, cyclic amines; Ν,Ν'-dibenzyl ethylenediamine, diethanolamine, ethylenediamine, meglumine, monosodium glutamate, polacrilin sodium, sodium alginate.
The photoprotective agents can be selected from metal oxides such as titanium oxide, iron oxide or zinc oxide.
In addition to these, other pharmaceutically acceptable excipients such as solubility modulators, electrolytes, colorants and coating agents can also be used in the formulation.
The formulations of the present invention are used by the oral route. Pharmaceutical formulations to be used orally can be in the form of tablets, capsules, soluble tablets, layered tablets, effervescent tablets, chewable tablets, film coated tablets, soluble granules, soluble powders, emulsions, suspensions, solutions or combinations thereof. The formulations of the present invention are preferably in tablet form and can optionally be film coated.
The formulations of the present invention can be produced by any methods in the prior art. These methods include wet granulation, dry granulation, direct compression, dry blending.
The formulations of the present invention are used for prevention and/or treatment of allergic and inflammatory diseases of skin or upper and respiratory tract such as seasonal allergic rhinitis, perennial allergic rhinitis, allergic sinusitis, atopic dermatitis, urticaria, allergic asthma, aspirin induced asthma, exercise induced asthma, and removal of symptoms related to said diseases.
Examples of pharmaceutical formulation of the present invention are given below. These examples are given in order to explain the invention, yet the invention is not restricted to these examples.
EXAMPLES
Example 1. Bilayer Tablet Formulation Comprising Montelukast Sodium and Desloratadine
The method proposed for preparation of the formulation given above is as follows:
1. Desloratadine and stabilizing agent in the desloratadine formulation are mixed with the diluent and the disintegrant; and the mixture is treated with sodium stearyl fumarate,
2. Montelukast and the diluent in the montelukast formulation are mixed with the binder and the disintegrant; and the mixture is treated with siliconized talc.
3. The two formulations prepared are compressed in bilayer tablet form by being fed to tablet compression machine separately and coated with film.
Table 1. Stability Study for Example 1
The bilayer tablet formulation produced according to the formulation and production method given above were stored at 60% of relative humidity rate and at 45 °C for 4 weeks (accelerated storage conditions) and the amounts of sulfoxide and N-formyl desloratadine impurity in the formulations were measured separately with HPLC (High-performance liquid chromatography) device. The results obtained are as follows:
According to the results of the stability study, the formulations comprising desloratadine and montelukast sodium prepared according to the formulation and the production method given in the example are considerably stabile in terms of both desloratadine and montelukast.
This unexpected effect has been achieved by formulating the two formulations separately and surprisingly by use of lubricant in different characteristics and amounts.
Example 2. Bilayer Tablet Formulation Comprising Montelukast Sodium and Desloratadine
The method proposed for preparation of the formulation given above is as follows:
1. Desloratadine and the stabilizing agent in the desloratadine formulation are mixed with the diluent, the disintegrant and colloidal silicone dioxide.
2. Talc is added into the mixture obtained and mixed; this mixture is mixed with sodium stearyl fumarate finally.
3. Montelukast and the diluent in montelukast formulation are mixed with the binder and the disintegrant; and the mixture is treated with siliconized talc.
The two different formulations prepared are compressed in bilayer tablet form being fed to tablet compression machine separately and coated with film.
Table 2. Stability Study for Example 2
The bilayer tablet formulation produced according to the formulation and the production method given above were stored at 60% of relative humidity rate and at 45 °C for 4 weeks (accelerated storage conditions) and the amounts of sulfoxide and N-formyl desloratadine impurity in the formulations were measured separately with HPLC (High-performance liquid chromatography) device. The results obtained are as follows:
According to the results of this stability study, the formulations comprising desloratadine and montelukast sodium prepared according to the formulation and production method given in the example are considerably stabile in terms of both desloratadine and montelukast.
Claims
1. A pharmaceutical formulation characterized in that said formulation comprises
I. Montelukast formulation comprising montelukast as active agent; a lubricant selected from a group comprising silicone oil, siliconized talc or liquid paraffin or binary or ternary combinations thereof as lubricant; and at least one other pharmaceutically acceptable excipient,
II. Desloratadine formulation comprising desloratadine as active agent; a lubricant selected from a group comprising talc, sodium stearyl fumarate or colloidal silicone dioxide or binary or ternary combinations thereof as lubricant; and at least one other pharmaceutically acceptable excipient.
2. The formulation according to claim 1 characterized in that montelukast formulation comprises lubricant in the range of 0.1 to 10% by weight; desloratadine formulation comprises lubricant in the range of 1 to 10% by weight.
3. The formulation according to claim 2 characterized in that montelukast formulation comprises lubricant in the range of 0.1 to 5% by weight; desloratadine formulation comprises lubricant in the range of 1 to 5% by weight.
4. The formulation according to claim 3 characterized in that both formulations comprise lubricant in the range of 2 to 5 % by weight.
5. The formulation according to claim 1 characterized in that the pharmaceutically acceptable excipients that can be used in the formulation are selected from a group comprising disintegrants, viscosity enhancing components, filling agents, drying agents, lubricants, diluents, binders, glidants, stabilizing agents, antifoaming agents, wetting agents, effervescent mixtures, sweeteners and flavoring agents.
6. The formulation according to claim 5 characterized in that said formulation comprises
I. Montelukast formulation comprising montelukast as active agent; a lubricant selected from a group comprising silicone oil, siliconized talk or liquid paraffin or combinations thereof; at least one pharmaceutically acceptable stabilizing agent; at least one disintegrant and at least one diluent,
II. Desloratadine formulation comprising desloratadine as active agent; a lubricant selected from a group comprising talc, sodium stearyl fumarate or colloidal silicone dioxide or binary or ternary combinations thereof; at least one pharmaceutically acceptable binder, at least one diluent, at least one disintegrant.
7. The formulation according to claims 5 and 6 characterized in that the diluents in the formulation are selected from a group comprising lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, calcium phosphate (dibasic and/or tribasic), calcium sulphate trihydrate, calcium sulphate dihydrate, calcium carbonate, kaoline, lactitol, cellulose powder, dextrose, dextrates, dextrin, sucrose, maltose, fructose, mannitol, directly compressible mannitol, directly compressible lactose, sorbitol and xylitol.
8. The formulation according to claims 5 and 6 characterized in that the disintegrants in the formulation are selected from cross-linked hydroxypropyl cellulose, croscarmellose sodium, polyvinylpyrrolidone, high molecular weight polymers, microcrystalline cellulose, corn starch, sodium starch glycolate, povidone, alginic acid, sodium alginate.
9. The formulation according to claims 5 and 6 characterized in that the binders in the formulation are selected from a group comprising potato, wheat or corn starch; microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone.
10. The formulation according to claims 5 and 6 characterized in that the stabilizing agents in the formulation are selected from a group comprising antioxidants, chelating agents, alkalinizing agents and photo protective agents.
11. The formulation according to claim 10 characterized in that the chelating agents are selected from disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or combinations thereof.
12. The formulation according to claim 10 characterized in that antioxidants are selected from a group comprising butylated hydroxy anisole (BHA), sodium ascorbate, butylated hydroxy toluene (BHT), sodium sulfite, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithine, ascorbyl palmitate, ethylendiamine tetraacetate.
3. The formulation according to claim 10 characterized in that the alkalinizing agents can be selected from alkaline metal salts such as sodium carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophospate, calcium hydrogen phosphate dehydrate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; and organic compounds such as primary, secondary and tertiary amines, cyclic amines; Ν,Ν'-dibenzyl ethylenediamine, diethanolamine, ethylenediamine, meglumine, monosodium glutamate, polacrilin sodium, sodium alginate.
14. A production method for the formulation according to any preceding claims characterized in that the formulations of the active agents are prepared separately and are combined in a single dosage form.
15. The production method according to claim 14 characterized in that the formulations of the active agents are prepared separately and are compressed in bilayer tablet form by being fed to tablet compression machine separately.
16. The pharmaceutical formulation according to claim 1 characterized in that said formulation is used for prevention and/or treatment of allergic and inflammatory diseases of skin or upper and respiratory tract such as seasonal allergic rhinitis, perennial allergic rhinitis, allergic sinusitis, atopic dermatitis, urticaria, allergic asthma, aspirin induced asthma, exercise induced asthma, and removal of symptoms related to said diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2010/9394 | 2010-11-11 | ||
TR2010/09394A TR201009394A2 (en) | 2010-11-11 | 2010-11-11 | Improved montelukast formulations. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012064303A2 true WO2012064303A2 (en) | 2012-05-18 |
WO2012064303A3 WO2012064303A3 (en) | 2012-07-19 |
Family
ID=45464073
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2011/000246 WO2012064304A2 (en) | 2010-11-11 | 2011-11-03 | Combinations comprising montelukast |
PCT/TR2011/000245 WO2012064303A2 (en) | 2010-11-11 | 2011-11-03 | Improved montelukast combinations |
PCT/TR2011/000244 WO2012064302A2 (en) | 2010-11-11 | 2011-11-03 | Improved montelukast formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2011/000246 WO2012064304A2 (en) | 2010-11-11 | 2011-11-03 | Combinations comprising montelukast |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2011/000244 WO2012064302A2 (en) | 2010-11-11 | 2011-11-03 | Improved montelukast formulations |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR201009394A2 (en) |
WO (3) | WO2012064304A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2677649C2 (en) * | 2013-02-21 | 2019-01-18 | Глэнмарк Фармасьютикалс Лимитед | Pharmaceutical compositions of montelucast and levocetirisine |
KR102226833B1 (en) * | 2013-06-28 | 2021-03-12 | 한미약품 주식회사 | Complex granule formulation having improved stability comprising levocetirizine and montelukast |
CN104666302B (en) * | 2013-11-27 | 2017-06-30 | 北京韩美药品有限公司 | Composition and preparation method thereof, oral liquid and preparation method thereof |
CN103655497B (en) * | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | A kind of Montelukast Sodium oral disnitegration tablet and preparation method thereof |
CN104840427B (en) * | 2014-02-13 | 2017-09-29 | 长春海悦药业股份有限公司 | A kind of pharmaceutical composition containing Menglusitena |
EP2949321A1 (en) * | 2014-05-26 | 2015-12-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer formulations of fexofenadine and montelukast |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0480717A1 (en) | 1990-10-12 | 1992-04-15 | Merck Frosst Canada Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
WO2007092031A1 (en) | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of montelukast sodium |
WO2010041277A2 (en) | 2008-10-06 | 2010-04-15 | Jubilant Organosys Limited | Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009122187A2 (en) * | 2008-04-03 | 2009-10-08 | Cipla Limited | Pharmaceutical composition |
TR200806298A2 (en) * | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Pharmaceutical formulation |
WO2010107404A1 (en) * | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
-
2010
- 2010-11-11 TR TR2010/09394A patent/TR201009394A2/en unknown
-
2011
- 2011-11-03 WO PCT/TR2011/000246 patent/WO2012064304A2/en active Application Filing
- 2011-11-03 WO PCT/TR2011/000245 patent/WO2012064303A2/en active Application Filing
- 2011-11-03 WO PCT/TR2011/000244 patent/WO2012064302A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0480717A1 (en) | 1990-10-12 | 1992-04-15 | Merck Frosst Canada Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
WO2007092031A1 (en) | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of montelukast sodium |
WO2010041277A2 (en) | 2008-10-06 | 2010-04-15 | Jubilant Organosys Limited | Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates |
Also Published As
Publication number | Publication date |
---|---|
WO2012064304A2 (en) | 2012-05-18 |
WO2012064302A3 (en) | 2012-07-19 |
WO2012064303A3 (en) | 2012-07-19 |
WO2012064302A2 (en) | 2012-05-18 |
TR201009394A2 (en) | 2012-06-21 |
WO2012064304A3 (en) | 2012-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6605303B1 (en) | Oral pharmaceutical extended release dosage form | |
KR102024955B1 (en) | Choline salt of an anti-inflammatory substituted cyclobutenedione compound | |
US20130296365A1 (en) | Quinoline derivative-containing pharmaceutical composition | |
WO2012064303A2 (en) | Improved montelukast combinations | |
WO2012064301A2 (en) | Physically improved tablet formulations | |
WO2010107404A1 (en) | Stable pharmaceutical combinations | |
WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
JP2017048174A (en) | Orally disintegrable tablet containing chemically stable coated particles containing drug substance | |
AU2005204014B2 (en) | Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent | |
US9750700B2 (en) | Imatinib mesylate oral pharmaceutical composition and process for preparation thereof | |
WO2013065068A1 (en) | Oral disintegrating composition of anti-histamine agents | |
WO2014104989A1 (en) | Pharmaceutical compositions comprising aripiprazole | |
JP2023513045A (en) | Amorphous nilotinib microparticles and uses thereof | |
JP2018065752A (en) | Silodosin-containing pharmaceutical composition and method for producing the same | |
WO2021112548A1 (en) | Pharmaceutical composition | |
WO2011000518A1 (en) | Pharmaceutical composition comprising desloratadine | |
CN106727381B (en) | Orally disintegrating tablet of dexlansoprazole sodium and preparation method thereof | |
WO2006111853A2 (en) | Stable solid dosage forms of acid labile drug | |
WO2013100879A1 (en) | Pharmaceutical compositions comprising quetiapine | |
WO2013109230A1 (en) | Pharmaceutical compositions comprising tadalafil | |
AU2017251803B2 (en) | Choline salt of an anti-inflammatory substituted cyclobutenedione compound | |
JP2011157298A (en) | Therapeutic agent of stomach ulcer | |
AU2012303675A1 (en) | Choline salt of an anti - inflammatory substituted cyclobutenedione compound | |
MXPA00005896A (en) | Oral pharmaceutical extended release dosage form | |
WO2011148253A2 (en) | Solid dosage forms of antipsychotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11805671 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11805671 Country of ref document: EP Kind code of ref document: A2 |